AIM: The aim of the study was to compare the dose-adjusted plasma levels of
carbamazepine (CBZ) among expressers and nonexpressers of cytochrome P450 3A5 …

Objective This study aims to investigate whether CYP3A5 polymorphisms affect steady-state
carbamazepine (CBZ) concentrations and therapeutic effects of CBZ monotherapy in …

Purpose: To determine the effects of CYP3A5 polymorphisms on carbamazepine (CBZ)
pharmacokinetic parameters when CBZ is used either as monotherapy or co-administered …

Abstract Background and Objective: Carbamazepine (CBZ) is metabolized mainly by the
CYP3A family of enzymes, which includes CYP3A4 and CYP3A5. Several studies have …

Background The genetically polymorphic cytochrome P450 enzymes are involved in the
metabolism and elimination of a number of widely used drugs. CYP3A5 exhibits remarkable …

Carbamazepine exhibits significant inter-individual variability in its efficacy and safety, which
leads to unpredictable therapy outcomes for the majority of patients. Although its complex …

Background and Objective The association between carbamazepine (CBZ) metabolism and
resistance in epilepsy and the genetic polymorphisms of CYP3A5 (rs776746 and rs15524) …

Objective: To investigate the association between the CYP3A5 genetic polymorphism and
the serum concentrations of carbamazepine (CBZ), to provide guidance for individualized …

Purpose The purpose of this study is to investigate the effect of two of the most important
functional CYP1A2 variations− 3860G> A and− 163C> A on carbamazepine …

Carbamazepine (CBZ) is a widely used antiepileptic drug with large interindividual
variability in serum concentrations. Previous studies found that CYP3A5* 3 (rs776746) …